Net Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2022

Earnings Per Share [Abstract]

Schedule of Computation of Basic and Diluted Net Loss Per Class A Common Share

The following table sets forth the computation of basic and diluted net loss per Class A common share attributable to Rani Holdings (in thousands, except per share data):

	Year Ended December 31,
	2022			2021
Numerator:
Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc.	$	(30,588	)	$	(8,331	)
Denominator:
Weighted average Class A common share outstanding—basic and diluted		23,817			19,534
Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc.—basic and diluted	$	(1.28	)	$	(0.43	)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following table shows the total outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per Class A common share attributable to Rani Holdings:

	Year Ended December 31,
	2022		2021
Paired Interests		24,116,444		29,290,391
Stock options		3,788,586		2,300,819
Non-corresponding Class A Units		1,387,471		1,545,522
Restricted stock units		665,500		596,500
Warrants		76,336		—
Restricted stock awards		67,389		113,173
Shares issuable pursuant to the ESPP		65,586		—
		30,167,312		33,846,405